Skip to content
Home - About us  - AstraZeneca in China    
AstraZeneca in China
Overview

AstraZeneca China has its headquarters in Shanghai, with 25 branch offices in major cities across China’s mainland. It has nearly 3,000 employees working in manufacturing, sales, clinical research and new product development. AstraZeneca is committed to being "In China, For China" with long-term planning and investment. In 2001, the company established its largest manufacturing site in Asia with a total investment of $170 million in Wuxi, China.

In May 2006, AstraZeneca announced to invest $100 million to establish its R&D base, the AstraZeneca Innovation Center China (ICC) in Shanghai. ICC puts its focus on Translational Science. Partnering with major hospitals and medical research ICC aims to fully support the development of China’s indigenous innovation. ICC’s initial therapeutic area is cancer.
AstraZeneca websites
Search
Quick Links
中文版